Consciousness Energy Healing Treatment Impacted the Isotopic Abundance Ratio of 6-Mercaptopurine (6-MP)

Consciousness Energy Healing Treatment Impacted the Isotopic Abundance Ratio of 6-Mercaptopurine (6-MP)

Materials Science, Pharmaceuticals

6-mercaptopurine (6-MP) is an antimetabolite antineoplastic chemotherapy drug. In this research work, the impact of the Trivedi Effect® on the structural properties and the isotopic abundance ratio of 6-MP were evaluated. The 6-MP test sample was divided into two-parts and termed as control and Biofield Energy Treated sample. The treated 6-MP only received the Trivedi Effect®-Consciousness Energy Healing Treatment remotely by a well-known Biofield Energy Healer, Mahendra Kumar Trivedi. The LC-MS spectra of both the 6-MP samples at retention time (Rt) 2.2 minutes showed the mass of the protonated molecular ion peak at m/z 173 [M+H]+. The peak area of the treated 6-MP was significantly increased by 92.07% compared to the control sample. The LC-MS based isotopic abundance ratio of PM+1+PM in the treated 6-MP was significantly increased by 34.79% compared with the control sample. Similarly, the GC-MS based isotopic abundance ratios of PM+1+PM and PM+2/PM in the treated 6-MP was significantly increased by 40.78% and 377.01% compared with the control sample. Thus, 13C, 2H, 15N, 33S, and 18O contributions from (C5H5N4S)+ to m/z 153 and 154 in the Biofield Energy Treated 6-MP were significantly increased as compared to the control 6-MP. The isotopic abundance ratio of PM+1+PM (2H/1H or 13C/12C or 15N/14N or 33S/32S) and PM+2/PM (34S/32S) in the treated 6-MP was significantly improved compared to the control sample. The significant increase in the peak area and isotopic abundance could be due to the interference of neutrino particles in the nucleus via the Trivedi Effect®. The increased isotopic abundance ratio of the treated 6-MP would improve the chemical bond strength, increase the physical and chemical stability of 6-MP in the body. The Biofield Energy Treated 6-MP would be better designing more efficacious pharmaceutical formulations that might offer increased bioavailability and therapeutic response against acute lymphocytic leukemia, Crohn’s disease, chronic myeloid leukemia, and ulcerative colitis, etc.

Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi and Snehasis Jana

Juniper Publishers

March 16, 2021

[no text]

[no text]

[no text]

[no text]

English

Journal Article

10.19080/NAPDD.2021.05.555673

[no text]